Protagen and Mikrogen have announced the closing of a collaboration agreement for the identification of typical autoantibody signatures in infectious diseases.
Dr Peter Schulz-Knappe, chief scientific officer and executive vice-president diagnostics at Protagen, said: 'Also classical infectious disease diagnostics can benefit from UNIarray, the proprietary technology platform of Protagen for the determination of indication specific auto-antibody signatures in serum.
'Within the scope of a mutual feasibility study performed with Mikrogen, we were able to show that infection-specific reactions of the immune system are accompanied by the generation of specific auto-antibodies, which are very useful for diagnostic developments,' he added.
Dr Erwin Soutschek, co-founder and managing director of Mikrogen, said: 'Our aim is the jointly development and marketing of characteristic marker panels for differential diagnosis of relevant infectious diseases.'
